Trial · NCT03928145

Efficacy of Chlorthalidone and Hydrochlorothiazide Combined With Amiloride on Blood Pressure in Primary Hypertension.

NCT03928145, Phase 3, Unknown, Hospital de Clinicas de Porto Alegre

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Efficacy of Chlorthalidone and Hydrochlorothiazide Combined With Amiloride on Blood Pressure in Primary Hypertension. Trials, record NCT03928145. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03928145

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Efficacy of Chlorthalidone and Hydrochlorothiazide Combined With Amiloride on Blood Pressure in Primary Hypertension.
NCT number: NCT03928145
Status: Unknown
Phases: Phase 3
Enrollment: 84 participants, estimated
Lead sponsor: Hospital de Clinicas de Porto Alegre
Conditions: Hypertension
Interventions: Chlorthalidone 25 mg, Hydrochlorothiazide 50 mg, Amiloride 20 mg, Amiloride 10 mg
First posted: 2019-04-25
Last updated: 2019-12-09

Source ClinicalTrials.gov

Registered outcomes18

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Mean change from baseline in 24-h systolic blood pressure measured by ABPM.	12 weeks	Difference between the treatment arms in mean change from baseline in 24-h systolic blood pressure measured by ABPM.
Primary	Mean change from baseline in 24-h diastolic blood pressure measured by ABPM.	12 weeks	Difference between the treatment arms in mean change from baseline in 24-h diastolic blood pressure measured by ABPM.
Secondary	Mean change from baseline in daytime and nighttime blood pressure measured by ABPM.	12 weeks	Difference between the treatment arms in mean change from baseline in daytime and nighttime systolic and diastolic blood pressure measured by ABPM.
Secondary	Mean change from baseline in systolic and diastolic blood pressure measured by office blood pressure.	12 weeks	Difference between the treatment arms in mean change from baseline in systolic and diastolic blood pressure measured by office blood pressure.
Secondary	Proportion of participants reporting adverse events.	12 weeks	Difference between treatment arms in the proportion of participants reporting adverse events.
Secondary	Mean change from baseline in total cholesterol.	12 weeks	Difference between the treatment arms in mean change from baseline in serum total cholesterol, measured in mg/dL.
Secondary	Mean change from baseline in HDL cholesterol (HDL-C).	12 weeks	Difference between the treatment arms in mean change from baseline in serum HDL cholesterol (HDL-C), measured in mg/dL.
Secondary	Mean change from baseline in LDL cholesterol (LDL-C).	12 weeks	Difference between the treatment arms in mean change from baseline in serum LDL cholesterol (LDL-C), measured in mg/dL.
Secondary	Mean change from baseline in triglycerides.	12 weeks	Difference between the treatment arms in mean change from baseline in serum triglycerides, measured in mg/dL.
Secondary	Mean change from baseline in creatinine.	12 weeks	Difference between the treatment arms in mean change from baseline in serum creatinine, measured in mg/dL.

1 to 10 of 18Source ClinicalTrials.gov

See all 18 registered outcomes

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
31843024	DERIVED	PubMed
42669885	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03928145

GET https://conductscience.org/api/trials/v1/NCT03928145/registered

API reference For AI assistants